Mina Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mina Chen has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Yanhui Liu
Guangdong Medical University, China
15 shared publications Mingrong Zuo
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
11 shared publicationsShuxin Zhang
Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu, China
11 shared publicationsSiliang Chen
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
10 shared publicationsWanchun Yang
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
10 shared publicationsYiyuan Cui
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
10 shared publications
Latest Publications
- 12 December 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (6) , 1281-1291
Chemotherapy induces multiple sclerosis-like neuropathologies that can be rescued by clobetasol
Chemotherapy is essential for cancer management yet frequently accompanied with adverse effects, particularly for temozolomide (TMZ), a frontline chemotherapeutic agent for glioma. Although clinical neurological abnormalities linked to TMZ have been observed, mechanisms underlying TMZ-induced neural impairments remain poorly understood, and effective interventions are lacking. Here, we demonstrated that TMZ chemotherapy induced neurodegenerations that recapitulated pathological features of multiple sclerosis, including demyelination, neuroinflammation and axonal degeneration. In adolescent mice, TMZ treatment resulted in severe white matter damage that spontaneously recovered, whereas in adult mice, moderate myelin damage persisted without recovery within the same timeframe. Importantly, we identified that clobetasol effectively reversed TMZ-induced white matter damage and trends toward anxiety and depression in adult mice by suppressing TMZ-induced AMPK activation and attenuating neuroinflammation, thereby promoting remyelination. Our findings reveal the previously underappreciated neural toxicities associated with TMZ chemotherapy and highlight the therapeutic efficacy of clobetasol in mitigating chemotherapy-induced neural impairment, providing a strategy to enhance the life quality of cancer patients.
- 12 December 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (6) , 1281-1291
Chemotherapy induces multiple sclerosis-like neuropathologies that can be rescued by clobetasol
Chemotherapy is essential for cancer management yet frequently accompanied with adverse effects, particularly for temozolomide (TMZ), a frontline chemotherapeutic agent for glioma. Although clinical neurological abnormalities linked to TMZ have been observed, mechanisms underlying TMZ-induced neural impairments remain poorly understood, and effective interventions are lacking. Here, we demonstrated that TMZ chemotherapy induced neurodegenerations that recapitulated pathological features of multiple sclerosis, including demyelination, neuroinflammation and axonal degeneration. In adolescent mice, TMZ treatment resulted in severe white matter damage that spontaneously recovered, whereas in adult mice, moderate myelin damage persisted without recovery within the same timeframe. Importantly, we identified that clobetasol effectively reversed TMZ-induced white matter damage and trends toward anxiety and depression in adult mice by suppressing TMZ-induced AMPK activation and attenuating neuroinflammation, thereby promoting remyelination. Our findings reveal the previously underappreciated neural toxicities associated with TMZ chemotherapy and highlight the therapeutic efficacy of clobetasol in mitigating chemotherapy-induced neural impairment, providing a strategy to enhance the life quality of cancer patients.
- Open Access
- 14 November 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 156
Neuronal differentiation regulator CEND1 coordinately suppresses tumor growth and energetics via AMPK signaling in brain glioma
The aggressive proliferation and metabolic adaptability of glioma contribute to poor clinical prognosis, necessitating novel targets concurrently reprogram glioma cells toward a neuron-like, less proliferative, and metabolically suppressed state. Here, we identified neuronal differentiation factor CEND1 as a candidate and explored its impact on glioma growth and metabolism. We demonstrated that CEND1 was significantly reduced in high-grade gliomas and inversely correlated with patient survival. Elevated CEND1 in glioma cells induced a neuron-like morphology, accompanied with attenuated proliferation and migration. CEND1 overexpression suppressed tumor growth and prolonged the survival of animal models of intracranial orthotopic tumor formation. Metabolomics and biochemical assays revealed that CEND1 inhibited PDH activity and mitochondrial oxidative phosphorylation, ultimately reducing ATP levels. Mechanistically, CEND1 activated AMPK to induce cell proliferation arrest and enhance metformin sensitivity. Altogether, our findings reveal that CEND1 coordinates neuronal differentiation with mitochondrial energetic metabolic suppression to exert anti-proliferative function in glioma, supporting its role as a potential target for glioma therapy.
- 14 November 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 156
Open AccessNeuronal differentiation regulator CEND1 coordinately suppresses tumor growth and energetics via AMPK signaling in brain glioma
The aggressive proliferation and metabolic adaptability of glioma contribute to poor clinical prognosis, necessitating novel targets concurrently reprogram glioma cells toward a neuron-like, less proliferative, and metabolically suppressed state. Here, we identified neuronal differentiation factor CEND1 as a candidate and explored its impact on glioma growth and metabolism. We demonstrated that CEND1 was significantly reduced in high-grade gliomas and inversely correlated with patient survival. Elevated CEND1 in glioma cells induced a neuron-like morphology, accompanied with attenuated proliferation and migration. CEND1 overexpression suppressed tumor growth and prolonged the survival of animal models of intracranial orthotopic tumor formation. Metabolomics and biochemical assays revealed that CEND1 inhibited PDH activity and mitochondrial oxidative phosphorylation, ultimately reducing ATP levels. Mechanistically, CEND1 activated AMPK to induce cell proliferation arrest and enhance metformin sensitivity. Altogether, our findings reveal that CEND1 coordinates neuronal differentiation with mitochondrial energetic metabolic suppression to exert anti-proliferative function in glioma, supporting its role as a potential target for glioma therapy.
- 24 October 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (47) , 4657-4670
Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling
The intricate tumor microenvironment largely influences chemoresistance in glioblastoma. Cancer-associated fibroblasts (CAFs) that modulate tumor progression have recently been identified as non-tumor stromal cells within the glioblastoma microenvironment. It remains unclear whether CAFs play a role in conferring chemoresistance to glioblastoma. The effects and mechanisms of CAFs on glioblastoma cells under temozolomide (TMZ) treatment are investigated by a series of patient-derived CAFs, orthotopic xenograft mouse models, and glioblastoma organoids (GBOs). Patient-derived cells have a transcriptomic and biomolecular profile of CAFs. CAFs promote temozolomide resistance in glioblastoma in vitro; these findings are consistent with results from intracranial tumor xenografts and GBO models. Mechanistically, CAFs express and secrete a significantly higher C-C motif chemokine ligand 2 (CCL2), which selectively enhances the activation of the ERK1/2 signaling in glioblastoma cells. Pharmacologically disrupting the CCL2-CCR2 axis or MEK1/2-ERK1/2 pathway effectively restores the therapeutic efficacy of temozolomide in glioblastoma cells and patient-derived GBOs. The decreased phosphor-ERK1/2 expression induced by trametinib treatment is also observed in glioblastoma cells following the CCL2-CCR2 axis inhibition. The present study suggests that targeting the CCL2/CCR2/ERK1/2 pathway may help overcome chemoresistance in glioblastomas caused by CAFs.
- 24 October 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (47) , 4657-4670
Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling
The intricate tumor microenvironment largely influences chemoresistance in glioblastoma. Cancer-associated fibroblasts (CAFs) that modulate tumor progression have recently been identified as non-tumor stromal cells within the glioblastoma microenvironment. It remains unclear whether CAFs play a role in conferring chemoresistance to glioblastoma. The effects and mechanisms of CAFs on glioblastoma cells under temozolomide (TMZ) treatment are investigated by a series of patient-derived CAFs, orthotopic xenograft mouse models, and glioblastoma organoids (GBOs). Patient-derived cells have a transcriptomic and biomolecular profile of CAFs. CAFs promote temozolomide resistance in glioblastoma in vitro; these findings are consistent with results from intracranial tumor xenografts and GBO models. Mechanistically, CAFs express and secrete a significantly higher C-C motif chemokine ligand 2 (CCL2), which selectively enhances the activation of the ERK1/2 signaling in glioblastoma cells. Pharmacologically disrupting the CCL2-CCR2 axis or MEK1/2-ERK1/2 pathway effectively restores the therapeutic efficacy of temozolomide in glioblastoma cells and patient-derived GBOs. The decreased phosphor-ERK1/2 expression induced by trametinib treatment is also observed in glioblastoma cells following the CCL2-CCR2 axis inhibition. The present study suggests that targeting the CCL2/CCR2/ERK1/2 pathway may help overcome chemoresistance in glioblastomas caused by CAFs.
- Open Access
- 6 October 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-14
Repeated ablations of mature Tmem10+ oligodendrocytes recapitulates key pathological features of multiple sclerosis with prolonged demyelination
Managing multiple sclerosis (MS), a chronic, neuroinflammatory and demyelinating disease, remains an unmet medical need. A great obstacle to developing therapeutic interventions altering the disease process is the lack of a suitable disease model recapitulating its core pathologies, especially the process of myelin damage and regeneration against the backdrop of persistent neuroinflammation. Now we report the generation and characterization of a new demyelination/remyelination model with key pathological features of MS through repeated ablations of Tmem10+ oligodendrocytes. Using the Tmem10-Cre driver that targets expression of diphtheria toxin receptor (DTR) in Tmem10+ (mature myelin-forming) oligodendrocytes, we conducted 3 rounds of Tmem10+ oligodendrocyte ablations over the span of 9 weeks in young adult mice by injecting diphtheria toxin (DT). Three rounds of the oligodendrocyte ablation caused prolonged demyelination and axonal injury in the backdrop of chronic neuroinflammation, including gliosis and lymphocyte infiltration. In response to the oligodendrocyte ablations, the proliferation and differentiation of OPCs were accelerated for the regeneration of myelin-forming oligodendrocytes, leading to spontaneous remyelination. This de-/re-myelination model presents a wide “time window” between the onset of demyelination and spontaneous remyelination, which makes it suitable for assessing the efficacy of therapeutic pro-remyelinating agents, as demonstrated by administering Benztropine to this demyelination model.
- 6 October 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-14
Open AccessRepeated ablations of mature Tmem10+ oligodendrocytes recapitulates key pathological features of multiple sclerosis with prolonged demyelination
Managing multiple sclerosis (MS), a chronic, neuroinflammatory and demyelinating disease, remains an unmet medical need. A great obstacle to developing therapeutic interventions altering the disease process is the lack of a suitable disease model recapitulating its core pathologies, especially the process of myelin damage and regeneration against the backdrop of persistent neuroinflammation. Now we report the generation and characterization of a new demyelination/remyelination model with key pathological features of MS through repeated ablations of Tmem10+ oligodendrocytes. Using the Tmem10-Cre driver that targets expression of diphtheria toxin receptor (DTR) in Tmem10+ (mature myelin-forming) oligodendrocytes, we conducted 3 rounds of Tmem10+ oligodendrocyte ablations over the span of 9 weeks in young adult mice by injecting diphtheria toxin (DT). Three rounds of the oligodendrocyte ablation caused prolonged demyelination and axonal injury in the backdrop of chronic neuroinflammation, including gliosis and lymphocyte infiltration. In response to the oligodendrocyte ablations, the proliferation and differentiation of OPCs were accelerated for the regeneration of myelin-forming oligodendrocytes, leading to spontaneous remyelination. This de-/re-myelination model presents a wide “time window” between the onset of demyelination and spontaneous remyelination, which makes it suitable for assessing the efficacy of therapeutic pro-remyelinating agents, as demonstrated by administering Benztropine to this demyelination model.
- 29 August 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 240, 559-565
Redox regulator LanCL1 suppresses glioma progression by coordinately inhibiting cell growth and regulating mitochondrial metabolism
- 29 August 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 240, 559-565
Redox regulator LanCL1 suppresses glioma progression by coordinately inhibiting cell growth and regulating mitochondrial metabolism
- Open Access
Glioma-associated fibroblasts promote glioblastoma resistance to temozolomide through CCL2-CCR2 paracrine signaling
Complicated tumor microenvironment contributes mostly to chemoresistance in glioblastoma. Glioma-associated fibroblasts (GAFs) were recently identified as non-tumor stromal cells in the glioblastoma microenvironment, whereas their function in glioblastoma chemoresistance is unclear. Herein, we interrogated the correlation between GAFs and chemoresistance of glioblastoma by examining a series of patient-derived GAFs and glioblastoma organoids (GBOs), revealing that GAFs could promote temozolomide resistance in glioblastoma. Mechanistically, C-C motif chemokine ligand 2 (CCL2) secreted by GAFs selectively activated the ERK1/2 signaling in glioblastoma cells to potentiate temozolomide resistance. Pharmacologically disrupting the CCL2-CCR2 axis or MEK1/2-ERK1/2 pathway effectively improved the therapeutic efficacy of temozolomide in GBM cells and patient-derived GBOs, and both decreased phospho-ERK1/2 expression. Collectively, our results identified that targeting the GAF-dominated CCL2-ERK1/2 pathway may be an alternative strategy to alleviate the GAF-mediated chemoresistance of glioblastoma. Significance: Comprehensive interpretation of the mutual support between tumor microenvironment and cancer cells is demanded for glioma with poor response rates to chemotherapy. This study demonstrates that GAFs promote the temozolomide resistance of glioblastoma by secreting cytokine CCL2 to activate ERK1/2 pathway, which may serve as a potential druggable candidate. Graphic Schematic illustration for GAFs mediated chemoresistance of GBMs and underlying mechanisms.: We demonstrate that Glioma-associated Fibroblasts (GAFs) grow in gliomas by isolating and identifying a panel of patient-derived GAFs. CCL2 secreted by GAFs stimulates CCR2 in GBM cells, which promotes activation of the ERK1/2 expression to potentiate GBM chemoresistance.
Open AccessGlioma-associated fibroblasts promote glioblastoma resistance to temozolomide through CCL2-CCR2 paracrine signaling
Complicated tumor microenvironment contributes mostly to chemoresistance in glioblastoma. Glioma-associated fibroblasts (GAFs) were recently identified as non-tumor stromal cells in the glioblastoma microenvironment, whereas their function in glioblastoma chemoresistance is unclear. Herein, we interrogated the correlation between GAFs and chemoresistance of glioblastoma by examining a series of patient-derived GAFs and glioblastoma organoids (GBOs), revealing that GAFs could promote temozolomide resistance in glioblastoma. Mechanistically, C-C motif chemokine ligand 2 (CCL2) secreted by GAFs selectively activated the ERK1/2 signaling in glioblastoma cells to potentiate temozolomide resistance. Pharmacologically disrupting the CCL2-CCR2 axis or MEK1/2-ERK1/2 pathway effectively improved the therapeutic efficacy of temozolomide in GBM cells and patient-derived GBOs, and both decreased phospho-ERK1/2 expression. Collectively, our results identified that targeting the GAF-dominated CCL2-ERK1/2 pathway may be an alternative strategy to alleviate the GAF-mediated chemoresistance of glioblastoma. Significance: Comprehensive interpretation of the mutual support between tumor microenvironment and cancer cells is demanded for glioma with poor response rates to chemotherapy. This study demonstrates that GAFs promote the temozolomide resistance of glioblastoma by secreting cytokine CCL2 to activate ERK1/2 pathway, which may serve as a potential druggable candidate. Graphic Schematic illustration for GAFs mediated chemoresistance of GBMs and underlying mechanisms.: We demonstrate that Glioma-associated Fibroblasts (GAFs) grow in gliomas by isolating and identifying a panel of patient-derived GAFs. CCL2 secreted by GAFs stimulates CCR2 in GBM cells, which promotes activation of the ERK1/2 expression to potentiate GBM chemoresistance.
- Open Access
- 12 May 2023
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 17
Impact of redox-related genes on tumor microenvironment immune characteristics and prognosis of high-grade gliomas
Introduction: High-grade glioma (HGG) defines a group of brain gliomas characterized by contrast enhancement, high tumor heterogeneity, and poor clinical outcome. Disturbed reduction–oxidation (redox) balance has been frequently associated with the development of tumor cells and their microenvironment (TME).Methods: To study the influence of redox balance on HGGs and their microenvironment, we collected mRNA-sequencing and clinical data of HGG patients from TCGA and CGGA databases and our own cohort. Redox-related genes (ROGs) were defined as genes in the MSigDB pathways with keyword “redox” that were differentially expressed between HGGs and normal brain samples. Unsupervised clustering analysis was used to discover ROG expression clusters. Over-representation analysis (ORA), gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were also employed to understand the biological implication of differentially expressed genes between HGG clusters. CIBERSORTx and ESTIMATE were used to profile the immune TME landscapes of tumors, and TIDE was used to evaluated the potential response to immune checkpoint inhibitors. Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression was used to construct HGG-ROG expression risk signature (GRORS).Results: Seventy-five ROGs were found and consensus clustering using the expression profile of ROGs divided the both IDH-mutant (IDHmut) and IDH-wildtype (IDHwt) HGGs into subclusters with different prognosis. Functional enrichment analysis revealed that the differential aggressiveness between redox subclusters in IDHmut HGGs were significantly associated with cell cycle regulation pathways, while IDHwt HGG redox subclusters showed differentially activated immune-related pathways. In silico TME analysis on immune landscapes in the TME showed that the more aggressive redox subclusters in both IDHmut and IDHwt HGGs may harbor a more diverse composition of tumor-infiltrating immune cells, expressed a higher level of immune checkpoints and were more likely to respond to immune checkpoint blockade. Next, we established a GRORS which showed AUCs of 0.787, 0.884, and 0.917 in predicting 1–3-year survival of HGG patients in the held-out validation datasets, and the C-index of a nomogram combining the GRORS and other prognostic information reached 0.835.Conclusion: Briefly, our results suggest that the expression pattern of ROGs was closely associated with the prognosis as well as the TME immune profile of HGGs, and may serve as a potential indicator for their response to immunotherapies.
- 12 May 2023
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 17
Open AccessImpact of redox-related genes on tumor microenvironment immune characteristics and prognosis of high-grade gliomas
Introduction: High-grade glioma (HGG) defines a group of brain gliomas characterized by contrast enhancement, high tumor heterogeneity, and poor clinical outcome. Disturbed reduction–oxidation (redox) balance has been frequently associated with the development of tumor cells and their microenvironment (TME).Methods: To study the influence of redox balance on HGGs and their microenvironment, we collected mRNA-sequencing and clinical data of HGG patients from TCGA and CGGA databases and our own cohort. Redox-related genes (ROGs) were defined as genes in the MSigDB pathways with keyword “redox” that were differentially expressed between HGGs and normal brain samples. Unsupervised clustering analysis was used to discover ROG expression clusters. Over-representation analysis (ORA), gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were also employed to understand the biological implication of differentially expressed genes between HGG clusters. CIBERSORTx and ESTIMATE were used to profile the immune TME landscapes of tumors, and TIDE was used to evaluated the potential response to immune checkpoint inhibitors. Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression was used to construct HGG-ROG expression risk signature (GRORS).Results: Seventy-five ROGs were found and consensus clustering using the expression profile of ROGs divided the both IDH-mutant (IDHmut) and IDH-wildtype (IDHwt) HGGs into subclusters with different prognosis. Functional enrichment analysis revealed that the differential aggressiveness between redox subclusters in IDHmut HGGs were significantly associated with cell cycle regulation pathways, while IDHwt HGG redox subclusters showed differentially activated immune-related pathways. In silico TME analysis on immune landscapes in the TME showed that the more aggressive redox subclusters in both IDHmut and IDHwt HGGs may harbor a more diverse composition of tumor-infiltrating immune cells, expressed a higher level of immune checkpoints and were more likely to respond to immune checkpoint blockade. Next, we established a GRORS which showed AUCs of 0.787, 0.884, and 0.917 in predicting 1–3-year survival of HGG patients in the held-out validation datasets, and the C-index of a nomogram combining the GRORS and other prognostic information reached 0.835.Conclusion: Briefly, our results suggest that the expression pattern of ROGs was closely associated with the prognosis as well as the TME immune profile of HGGs, and may serve as a potential indicator for their response to immunotherapies.
- Open Access
- 10 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1038272
Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
Glioma is the most common malignant tumor in the central nervous system. The impact of metabolism on cancer development and the immune microenvironment landscape has recently gained broad attention. Purines are involved in multiple metabolic pathways. It has been proved that purine metabolism could regulate malignant biological behaviors and response to immune checkpoint inhibitors in multiple cancers. However, the relationship of purine metabolism with clinicopathological features and the immune landscape of glioma remains unclear. In this study, we explored the relationships between the expression of purine metabolism-related genes (PuMGs) and tumor features, including prognosis and microenvironment of glioma, based on analyses of 1,523 tumors from 4 public databases and our cohort. Consensus clustering based on 136 PuMGs classified the glioma patients into two clusters with significantly distinguished prognosis and immune microenvironment landscapes. Increased immune infiltration was associated with more aggressive gliomas. The prognostic Purine Metabolism-Related Genes Risk Signature (PuMRS), based on 11 critical PuMGs, stratified the patients into PuMRS low- and high-risk groups in the training set and was validated by validation sets from multiple cohorts. The high-risk group presented with significantly shorter overall survival, and further survival analysis demonstrated that the PuMRS was an independent prognostic factor in glioma. The nomogram combining PuMRS and other clinicopathological factors showed satisfactory accuracy in predicting glioma patients’ prognosis. Furthermore, analyses of the tumor immune microenvironment suggested that higher PuMRS was correlated with increased immune cell infiltration and gene expression signatures of “hotˮ tumors. Gliomas in the PuMRS high-risk group presented a higher expression level of multiple immune checkpoints, including PD-1 and PD-L1, and a better-predicted therapy response to immune checkpoint inhibitors. In conclusion, our study elucidated the relationship between the expression level of PuMGs and the aggressiveness of gliomas. Our study also endorsed the application of PuMRS to construct a new robust model for the prognosis evaluation of glioma patients. The correlations between the profiles of PuMGs expression and tumor immune microenvironment potentially provided guidance for immunotherapy in glioma.
- 10 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1038272
Open AccessPurine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
Glioma is the most common malignant tumor in the central nervous system. The impact of metabolism on cancer development and the immune microenvironment landscape has recently gained broad attention. Purines are involved in multiple metabolic pathways. It has been proved that purine metabolism could regulate malignant biological behaviors and response to immune checkpoint inhibitors in multiple cancers. However, the relationship of purine metabolism with clinicopathological features and the immune landscape of glioma remains unclear. In this study, we explored the relationships between the expression of purine metabolism-related genes (PuMGs) and tumor features, including prognosis and microenvironment of glioma, based on analyses of 1,523 tumors from 4 public databases and our cohort. Consensus clustering based on 136 PuMGs classified the glioma patients into two clusters with significantly distinguished prognosis and immune microenvironment landscapes. Increased immune infiltration was associated with more aggressive gliomas. The prognostic Purine Metabolism-Related Genes Risk Signature (PuMRS), based on 11 critical PuMGs, stratified the patients into PuMRS low- and high-risk groups in the training set and was validated by validation sets from multiple cohorts. The high-risk group presented with significantly shorter overall survival, and further survival analysis demonstrated that the PuMRS was an independent prognostic factor in glioma. The nomogram combining PuMRS and other clinicopathological factors showed satisfactory accuracy in predicting glioma patients’ prognosis. Furthermore, analyses of the tumor immune microenvironment suggested that higher PuMRS was correlated with increased immune cell infiltration and gene expression signatures of “hotˮ tumors. Gliomas in the PuMRS high-risk group presented a higher expression level of multiple immune checkpoints, including PD-1 and PD-L1, and a better-predicted therapy response to immune checkpoint inhibitors. In conclusion, our study elucidated the relationship between the expression level of PuMGs and the aggressiveness of gliomas. Our study also endorsed the application of PuMRS to construct a new robust model for the prognosis evaluation of glioma patients. The correlations between the profiles of PuMGs expression and tumor immune microenvironment potentially provided guidance for immunotherapy in glioma.
- Open Access
- 1 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1061597
Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma
Glioma is the most common malignant tumor in the central nervous system with no significant therapeutic breakthrough in recent years. Most attempts to apply immunotherapy in glioma have failed. Tryptophan and its metabolism can regulate malignant features of cancers and reshape immune microenvironment of tumors. However, the role of tryptophan metabolism in glioma remains unclear. In current study, we explored the relationships between the expression pattern of tryptophan metabolism-related genes (TrMGs) and tumor characteristics, including prognosis and tumor microenvironment of gliomas through analyzing 1,523 patients’ samples from multiple public databases and our own cohort. Based on expression of TrMGs, K-means clustering analysis stratified all glioma patients into two clusters with significantly different TrMG expression patterns, clinicopathological features and immune microenvironment. Furthermore, we constructed a tryptophan metabolism-related genes signature (TrMRS) based on seven essential TrMGs to classify the patients into TrMRS low- and high-risk groups and validated the prognostic value of the TrMRS in multiple cohorts. Higher TrMRS represented for potentially more active tryptophan catabolism, which could subsequently lead to less tryptophan in tumor. The TrMRS high-risk group presented with shorter overall survival, and further analysis confirmed TrMRS as an independent prognostic factor in gliomas. The nomograms uniting TrMRS with other prognostic factors manifested with satisfactory efficacy in predicting the prognosis of glioma patients. Additionally, analyses of tumor immune landscapes demonstrated that higher TrMRS was correlated with more immune cell infiltration and “hot” immunological phenotype. TrMRS was also demonstrated to be positively correlated with the expression of multiple immunotherapy targets, including PD1 and PD-L1. Finally, the TrMRS high-risk group manifested better predicted response to immune checkpoint inhibitors. In conclusion, our study illustrated the relationships between expression pattern of TrMGs and characteristics of gliomas, and presented a novel model based on TrMRS for prognosis prediction in glioma patients. The association between TrMRS and tumor immune microenvironment of gliomas indicated an important role of tryptophan and its metabolism in reshaping immune landscape and the potential ability to guide the application of immunotherapy for gliomas.
- 1 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1061597
Open AccessPrognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma
Glioma is the most common malignant tumor in the central nervous system with no significant therapeutic breakthrough in recent years. Most attempts to apply immunotherapy in glioma have failed. Tryptophan and its metabolism can regulate malignant features of cancers and reshape immune microenvironment of tumors. However, the role of tryptophan metabolism in glioma remains unclear. In current study, we explored the relationships between the expression pattern of tryptophan metabolism-related genes (TrMGs) and tumor characteristics, including prognosis and tumor microenvironment of gliomas through analyzing 1,523 patients’ samples from multiple public databases and our own cohort. Based on expression of TrMGs, K-means clustering analysis stratified all glioma patients into two clusters with significantly different TrMG expression patterns, clinicopathological features and immune microenvironment. Furthermore, we constructed a tryptophan metabolism-related genes signature (TrMRS) based on seven essential TrMGs to classify the patients into TrMRS low- and high-risk groups and validated the prognostic value of the TrMRS in multiple cohorts. Higher TrMRS represented for potentially more active tryptophan catabolism, which could subsequently lead to less tryptophan in tumor. The TrMRS high-risk group presented with shorter overall survival, and further analysis confirmed TrMRS as an independent prognostic factor in gliomas. The nomograms uniting TrMRS with other prognostic factors manifested with satisfactory efficacy in predicting the prognosis of glioma patients. Additionally, analyses of tumor immune landscapes demonstrated that higher TrMRS was correlated with more immune cell infiltration and “hot” immunological phenotype. TrMRS was also demonstrated to be positively correlated with the expression of multiple immunotherapy targets, including PD1 and PD-L1. Finally, the TrMRS high-risk group manifested better predicted response to immune checkpoint inhibitors. In conclusion, our study illustrated the relationships between expression pattern of TrMGs and characteristics of gliomas, and presented a novel model based on TrMRS for prognosis prediction in glioma patients. The association between TrMRS and tumor immune microenvironment of gliomas indicated an important role of tryptophan and its metabolism in reshaping immune landscape and the potential ability to guide the application of immunotherapy for gliomas.
- 26 October 2022
- Published by Springer Nature in Neurosurgical Review
- Vol. 45 (6) , 3771-3778
Extraventricular site indicates higher grade but better prognosis in adult supratentorial ependymomas: a 14-year single-center retrospective cohort
Supratentorial extraventricular ependymoma (STEE) and supratentorial intraventricular ependymoma (STIE) are two subsets of supratentorial ependymoma (SE). These two subsets have similar gene features and only differ in original sites: STEE occurs in the brain parenchyma, and STIE is located in ventricles and surrounded by cerebral spinal fluid. The present study aims to depict the diversities of these two subsets and elucidate the potential effects of the anatomic site on the tumor with the same type, grade, and molecular features. Sixty-six consecutive adult SE patients from 2008 to 2021 were enrolled in our study. Clinical data, pathological features, and long-term outcomes were analyzed retrospectively. Results demonstrated that adult STEE presented with a higher proportion of WHO grade 3 (P = .028) and higher Ki-67 index (≥10%) (P = .019) compared to adult STIE. Survival analysis demonstrated that patients of grade 3 STEE exhibited a significantly longer overall survival (OS) than patients of grade 3 STIE (median OS, 24.4 months vs. 13.0 months; P = .004). Grade 2 (hazard ratio (HR) = 0.217; P < .001) and gross total resection (GTR) (HR = 0.156; P < .001) were identified as favorable prognostic factors for all adult SE. The STEE was also associated with a lesser hazard of death for patients of grade 3 on multivariate analysis (HR = 0.263; P = .047). These findings suggested that the extraventricular site was an indicator for higher grade and better prognosis in adult supratentorial ependymoma.
- 26 October 2022
- Published by Springer Nature in Neurosurgical Review
- Vol. 45 (6) , 3771-3778
Extraventricular site indicates higher grade but better prognosis in adult supratentorial ependymomas: a 14-year single-center retrospective cohort
Supratentorial extraventricular ependymoma (STEE) and supratentorial intraventricular ependymoma (STIE) are two subsets of supratentorial ependymoma (SE). These two subsets have similar gene features and only differ in original sites: STEE occurs in the brain parenchyma, and STIE is located in ventricles and surrounded by cerebral spinal fluid. The present study aims to depict the diversities of these two subsets and elucidate the potential effects of the anatomic site on the tumor with the same type, grade, and molecular features. Sixty-six consecutive adult SE patients from 2008 to 2021 were enrolled in our study. Clinical data, pathological features, and long-term outcomes were analyzed retrospectively. Results demonstrated that adult STEE presented with a higher proportion of WHO grade 3 (P = .028) and higher Ki-67 index (≥10%) (P = .019) compared to adult STIE. Survival analysis demonstrated that patients of grade 3 STEE exhibited a significantly longer overall survival (OS) than patients of grade 3 STIE (median OS, 24.4 months vs. 13.0 months; P = .004). Grade 2 (hazard ratio (HR) = 0.217; P < .001) and gross total resection (GTR) (HR = 0.156; P < .001) were identified as favorable prognostic factors for all adult SE. The STEE was also associated with a lesser hazard of death for patients of grade 3 on multivariate analysis (HR = 0.263; P = .047). These findings suggested that the extraventricular site was an indicator for higher grade and better prognosis in adult supratentorial ependymoma.